ArticleBrain communications2020
Role of glucosamine in development of diabetic neuropathy independent of the aldose reductase pathway.
Article in Brain communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 26 citations in OpenAlex.
- Metabolomics in Pathogenic Pathways and Targeted Therapies for Diabetic Neuropathy: A Comprehensive Review.Metabolites · 2025Review
- Hypertension is associated with the reduction in epidermal small fibres independently of sural nerve inflammation in type 2 diabetic subjects.Journal of neurochemistry · 2025Article
- Role of Exogenous Pyruvate in Maintaining Adenosine Triphosphate Production under High-Glucose Conditions through PARP-Dependent Glycolysis and PARP-Independent Tricarboxylic Acid Cycle.International journal of molecular sciences · 2024Article
- Pathological evaluation of the pathogenesis of diabetes mellitus and diabetic peripheral neuropathy.Pathology international · 2024Review
- Tryptophan metabolism and small fibre neuropathy: a correlation study.Brain communications · 2024Article
- Current Concepts in the Molecular Mechanisms and Management of Diabetic Neuropathy by Pharmacotherapeutics and Natural Compounds.Central nervous system agents in medicinal chemistry · 2024Review
- Immortalized Schwann cell lines as useful tools for pathogenesis-based therapeutic approaches to diabetic peripheral neuropathy.Frontiers in endocrinology · 2024Review
- Ultra-high performance liquid chromatography coupled to tandem mass spectrometry-based metabolomics study of diabetic distal symmetric polyneuropathy.Journal of diabetes investigation · 2023Article
- The Aldose Reductase Inhibitor Epalrestat Maintains Blood-Brain Barrier Integrity by Enhancing Endothelial Cell Function during Cerebral Ischemia.Molecular neurobiology · 2023Article
- Advantages of omics approaches for elucidating metabolic changes in diabetic peripheral neuropathy.Frontiers in endocrinology · 2023Review
- Application of Metabolomics and Traditional Chinese Medicine for Type 2 Diabetes Mellitus Treatment.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Review
- RAGE activation in macrophages and development of experimental diabetic polyneuropathy.JCI insight · 2022Article
- Sphingolipid metabolism plays a key role in diabetic peripheral neuropathy.Metabolomics : Official journal of the Metabolomic Society · 2022Article
- Pharmacotherapy of Painful Diabetic Neuropathy: A Clinical Update.Sisli Etfal Hastanesi tip bulteni · 2022Review
- Silencing of PFKFB3 protects podocytes against high glucose‑induced injury by inducing autophagy.Molecular medicine reports · 2021Article
- Physiological and Pathological Roles of Aldose Reductase.Metabolites · 2021Review
- Diabetic heart disease: A clinical update.World journal of diabetes · 2021Review
- Aldose Reductase and the Polyol Pathway in Schwann Cells: Old and New Problems.International journal of molecular sciences · 2021Review
- Pathogenesis and Molecular Treatment Strategies of Diabetic Neuropathy Collateral Glucose-Utilizing Pathways in Diabetic Polyneuropathy.International journal of molecular sciences · 2020Review
- Increased Oxidative Stress Underlies Abnormal Pain Threshold in a Normoglycemic Japanese Population.International journal of molecular sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long-term metabolic aberrations contribute to the development of diabetic neuropathy but the precise mechanism or mechanisms remains elusive. We have previously shown that aldose reductase-deficient mice exhibit delayed onset and progression of neuropathy following induction of diabetes, suggesting a role both for downstream metabolites of this enzyme and also for other unrelated pathways. In this study, we have utilized comprehensive metabolomics analyses to identify potential neurotoxic metabolites in nerve of diabetic mice and explored the mechanism of peripheral nerve injury. Aldose reductase knockout and control C57Bl/6J mice were made diabetic by injection of streptozotocin and followed for 8-16 weeks. Diabetic aldose reductase knockout mice exhibited delayed onset of nerve conduction slowing compared to diabetic wild-type mice. The sciatic nerves from aldose reductase knockout mice exposed to 12 weeks of diabetes were used for metabolomics analysis and compared with analyses of nerves from age-matched diabetic wild-type mice as well as non-diabetic aldose reductase knockout and wild-type mice. Neurotoxicity of candidate metabolites was evaluated using cultured Schwann cells and dorsal root ganglion neurons, and further confirmed
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.